AORT — Artivion, Inc.

Summary of Artivion Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 2025 Results:

  • Total adjusted revenues: $118.3 million, up 18.5% year-over-year.
  • Adjusted EBITDA: $22.7 million, a 29% increase from $17.6 million in Q4 2024.
  • Adjusted EBITDA margin: 19.2%, improved by 110 basis points year-over-year.

• Full Year 2025 Results:

  • Total adjusted revenues: $443.6 million, up 13% year-over-year.
  • Adjusted EBITDA: $89.7 million, a 26% increase, with an adjusted EBITDA margin of 20.2%, up 190 basis points from 2024.
  • Free cash flow for the year: approximately $1 million.

2. Strategic Updates and Business Highlights

• Product Performance:

  • Stent grafts revenue grew 36%, driven by AMDS growth in the U.S. and international markets.
  • On-X revenues increased 24%, supported by new clinical data enhancing market share.
  • Tissue processing revenue grew 6%, recovering from prior cybersecurity impacts.
  • BioGlue revenues remained flat.

• Clinical Advancements:

  • Positive data from AMDS PERSEVERE and NEXUS TRIOMPHE trials presented at STS Annual Meeting, reinforcing the efficacy of AMDS technology.
  • Progress on the ARTIZEN trial for Arcevo LSA, with expectations for FDA approval in 2029.

• Regulatory Updates:

  • Filed the fourth and final module with the FDA for AMDS, targeting PMA approval in mid-2026.

3. Forward Guidance and Outlook

• 2026 Revenue Growth:

  • Expected constant currency growth of 10% to 14%, translating to reported revenues of $486 million to $504 million.
  • Anticipated adjusted EBITDA growth of 18% to 22%, with a margin expansion of approximately 150 basis points.
  • Specific growth expectations:
    • Stent grafts: low 20s growth.
    • On-X: mid-teens growth.
    • BioGlue: mid-single digits growth.
    • Tissue revenue: expected to remain flat.

• Capital Expenditures:

  • Projected CapEx for 2026: approximately $50 million, primarily for On-X capacity expansion and IT system improvements.

4. Bad News, Challenges, or Points of Concern

• Italian Payback Legislation:

  • A $2.3 million revenue adjustment related to Italian payback obligations impacted Q4 and full-year results, although future impacts are expected to be minimal.

• Cybersecurity Incident Recovery:

  • The lingering effects of the cybersecurity incident from Q4 2024 continue to influence growth rates, particularly in tissue processing.

• Market Competition:

  • The NEXUS device faces competition from an already approved product, necessitating effective differentiation and market penetration strategies.

5. Notable Q&A Insights

• AMDS Growth:

  • Management indicated that AMDS is still in early stages of market penetration, with significant growth potential as they expand into new accounts.

• NEXUS Market Opportunity:

  • The NEXUS device is expected to target high-risk patients, with a U.S. market potential of $150 million. The rollout will require extensive training for specialized surgeons.

• Pricing Strategy:

  • Pricing for AMDS ($25,000) and NEXUS ($50,000) remains competitive, with demand showing relative price insensitivity.

• DRG Code Impact:

  • The new DRG code implemented in October is seen as a tailwind, though its immediate effect on hospital bureaucracy remains uncertain.

Overall, Artivion reported strong financial performance in 2025, driven by robust product growth and clinical advancements, while navigating challenges related to regulatory impacts and cybersecurity recovery. The outlook for 2026 remains positive, with expectations for continued growth across key product lines.